Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects

Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amo...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 93; no. 4; pp. 2160 - 2167
Main Authors Criscuolo, Elena, Diotti, Roberta A., Strollo, Marta, Rolla, Serena, Ambrosi, Alessandro, Locatelli, Massimo, Burioni, Roberto, Mancini, Nicasio, Clementi, Massimo, Clementi, Nicola
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.04.2021
John Wiley and Sons Inc
Subjects
Online AccessGet full text
ISSN0146-6615
1096-9071
1096-9071
DOI10.1002/jmv.26605

Cover

Loading…
Abstract Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS‐CoV‐2 S1/S2 IgG by DiaSorin and Elecsys Anti‐SARS‐CoV‐2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory‐confirmed coronavirus disease‐2019 (COVID‐19) subjects. Secondly, 85 negative serum samples collected before the SARS‐CoV‐2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS‐CoV‐2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS‐CoV‐2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines. Highlights A comparative analysis between two serologic assays for the detection of antibodies directed against SARS‐CoV‐2 was carried out on sera from subjects testing positive for SARS‐CoV‐2 nasopharyngeal swabs. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased for samples collected after 15 days. A poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study.
AbstractList Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS‐CoV‐2 S1/S2 IgG by DiaSorin and Elecsys Anti‐SARS‐CoV‐2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory‐confirmed coronavirus disease‐2019 (COVID‐19) subjects. Secondly, 85 negative serum samples collected before the SARS‐CoV‐2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS‐CoV‐2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS‐CoV‐2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines. Highlights A comparative analysis between two serologic assays for the detection of antibodies directed against SARS‐CoV‐2 was carried out on sera from subjects testing positive for SARS‐CoV‐2 nasopharyngeal swabs. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased for samples collected after 15 days. A poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study.
Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory-confirmed coronavirus disease-2019 (COVID-19) subjects. Secondly, 85 negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS-CoV-2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.
Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS‐CoV‐2 S1/S2 IgG by DiaSorin and Elecsys Anti‐SARS‐CoV‐2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory‐confirmed coronavirus disease‐2019 (COVID‐19) subjects. Secondly, 85 negative serum samples collected before the SARS‐CoV‐2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS‐CoV‐2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS‐CoV‐2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.
Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory-confirmed coronavirus disease-2019 (COVID-19) subjects. Secondly, 85 negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS-CoV-2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory-confirmed coronavirus disease-2019 (COVID-19) subjects. Secondly, 85 negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS-CoV-2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.
Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS‐CoV‐2 S1/S2 IgG by DiaSorin and Elecsys Anti‐SARS‐CoV‐2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory‐confirmed coronavirus disease‐2019 (COVID‐19) subjects. Secondly, 85 negative serum samples collected before the SARS‐CoV‐2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS‐CoV‐2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS‐CoV‐2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines. A comparative analysis between two serologic assays for the detection of antibodies directed against SARS‐CoV‐2 was carried out on sera from subjects testing positive for SARS‐CoV‐2 nasopharyngeal swabs. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased for samples collected after 15 days. A poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study.
Author Criscuolo, Elena
Diotti, Roberta A.
Locatelli, Massimo
Rolla, Serena
Strollo, Marta
Clementi, Nicola
Mancini, Nicasio
Clementi, Massimo
Ambrosi, Alessandro
Burioni, Roberto
AuthorAffiliation 4 Laboratory of Medical Microbiology and Virology IRCCS San Raffaele Hospital Milan Italy
3 Faculty of Medicine and Surgery Vita‐Salute San Raffaele University Milan Italy
2 Laboratory Medicine Service IRCCS San Raffaele Hospital Milan Italy
1 Laboratory of Medical Microbiology and Virology Vita‐Salute San Raffaele University Milan Italy
AuthorAffiliation_xml – name: 4 Laboratory of Medical Microbiology and Virology IRCCS San Raffaele Hospital Milan Italy
– name: 2 Laboratory Medicine Service IRCCS San Raffaele Hospital Milan Italy
– name: 3 Faculty of Medicine and Surgery Vita‐Salute San Raffaele University Milan Italy
– name: 1 Laboratory of Medical Microbiology and Virology Vita‐Salute San Raffaele University Milan Italy
Author_xml – sequence: 1
  givenname: Elena
  orcidid: 0000-0003-0185-3147
  surname: Criscuolo
  fullname: Criscuolo, Elena
  organization: Vita‐Salute San Raffaele University
– sequence: 2
  givenname: Roberta A.
  surname: Diotti
  fullname: Diotti, Roberta A.
  organization: Vita‐Salute San Raffaele University
– sequence: 3
  givenname: Marta
  surname: Strollo
  fullname: Strollo, Marta
  organization: IRCCS San Raffaele Hospital
– sequence: 4
  givenname: Serena
  surname: Rolla
  fullname: Rolla, Serena
  organization: IRCCS San Raffaele Hospital
– sequence: 5
  givenname: Alessandro
  orcidid: 0000-0003-1976-5663
  surname: Ambrosi
  fullname: Ambrosi, Alessandro
  organization: Vita‐Salute San Raffaele University
– sequence: 6
  givenname: Massimo
  surname: Locatelli
  fullname: Locatelli, Massimo
  organization: IRCCS San Raffaele Hospital
– sequence: 7
  givenname: Roberto
  surname: Burioni
  fullname: Burioni, Roberto
  organization: Vita‐Salute San Raffaele University
– sequence: 8
  givenname: Nicasio
  surname: Mancini
  fullname: Mancini, Nicasio
  organization: IRCCS San Raffaele Hospital
– sequence: 9
  givenname: Massimo
  surname: Clementi
  fullname: Clementi, Massimo
  organization: IRCCS San Raffaele Hospital
– sequence: 10
  givenname: Nicola
  orcidid: 0000-0002-1822-9861
  surname: Clementi
  fullname: Clementi, Nicola
  email: clementi.nicola@hsr.it
  organization: IRCCS San Raffaele Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33064340$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1u1DAUhS1URKeFBS-ALLGhi7T-iZ1kg1SNoICKkCiUpeU4N8VDYg-2M9Ww4hF4Rp4ET2eKoIKNf3S_c3ysc4D2nHeA0GNKjikh7GQxro6ZlETcQzNKGlk0pKJ7aEZoKQspqdhHBzEuCCF1w9gDtM85kSUvyQwtP4H-go0PAQadrHe4hXQN4LB2yba-W-NkE4SY7x12MKWgB_vNuiusTbIrm9bYOhwhaNwHP-KL0_cXP7__mPvLvLI868Ek6HCc2kU-xYfofq-HCI92-yH6-PLFh_mr4vzd2ev56XlhBK9E0dGadXUNpqVSSNELwfu-pYzJWpDOlGXdCwN91ZDakJrSpuK6qTRpCMhOg-CH6PnWdzm1I3QG3Ca5WgY76rBWXlv198TZz-rKr1QlK1EJng2e7QyC_zpBTGq00cAwaAd-ioqVgtai4WTz1tM76MJPweXvZaohlNVcyEw9-TPR7yi3ZWTgZAuY4GMM0Ctj000pOaAdFCVqU7fKdauburPi6I7i1vRf7M792g6w_j-o3ry93Cp-AfIovGs
CitedBy_id crossref_primary_10_3390_ani12111459
crossref_primary_10_3390_vaccines10050801
crossref_primary_10_1136_annrheumdis_2021_220647
crossref_primary_10_1136_annrheumdis_2021_221735
crossref_primary_10_3346_jkms_2022_37_e135
crossref_primary_10_1136_ard_2022_222550
crossref_primary_10_1016_j_heliyon_2024_e24513
crossref_primary_10_1038_s41598_021_91746_7
crossref_primary_10_3390_vaccines9111357
crossref_primary_10_3390_diagnostics12010085
crossref_primary_10_3390_vaccines10071044
crossref_primary_10_1097_MD_0000000000029362
crossref_primary_10_1177_23742895211002802
crossref_primary_10_3390_vaccines11030598
crossref_primary_10_1016_j_vaccine_2022_03_001
crossref_primary_10_3390_ani13223498
crossref_primary_10_1111_trf_16693
crossref_primary_10_3390_v14010061
crossref_primary_10_3390_v14061232
crossref_primary_10_3390_life12122064
crossref_primary_10_1111_trf_17083
crossref_primary_10_1136_annrheumdis_2021_221916
crossref_primary_10_3390_vaccines11081380
crossref_primary_10_3389_fimmu_2024_1323406
crossref_primary_10_3389_fimmu_2022_833085
crossref_primary_10_1093_rheumatology_keac103
crossref_primary_10_1016_j_vaccine_2024_07_026
crossref_primary_10_3346_jkms_2021_36_e158
crossref_primary_10_1128_spectrum_01315_22
crossref_primary_10_1056_NEJMoa2109072
crossref_primary_10_3390_vaccines11020476
crossref_primary_10_1111_apa_16031
crossref_primary_10_4049_jimmunol_2200487
crossref_primary_10_3390_vaccines10060901
crossref_primary_10_1016_j_clim_2022_108961
crossref_primary_10_3390_vaccines11040819
crossref_primary_10_3390_life14070791
crossref_primary_10_3390_ijms25105509
crossref_primary_10_3390_vaccines9070714
crossref_primary_10_3390_jpm11121253
crossref_primary_10_3390_vaccines10020260
crossref_primary_10_3390_covid4080091
Cites_doi 10.15557/PiMR.2020.0024
10.1101/2020.03.18.20038018
10.1038/s41420-020-0275-2
10.2307/2531595
10.1101/2020.03.30.20047365
10.1101/2020.07.09.20148429
10.1016/j.immuni.2020.03.007
10.1038/s41541-020-0198-1
10.1128/JCM.00461-20
10.3389/fmolb.2020.00157
10.1002/(SICI)1097-0258(19971015)16:19<2143::AID-SIM655>3.0.CO;2-3
10.1101/2020.07.21.20159178
10.1007/s11427-020-1805-0
10.1016/S1473-3099(20)30196-1
10.1128/JCM.01224-20
ContentType Journal Article
Copyright 2020 Wiley Periodicals LLC
2020 Wiley Periodicals LLC.
2021 Wiley Periodicals LLC
Copyright_xml – notice: 2020 Wiley Periodicals LLC
– notice: 2020 Wiley Periodicals LLC.
– notice: 2021 Wiley Periodicals LLC
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7TK
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
5PM
DOI 10.1002/jmv.26605
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Virology and AIDS Abstracts
Technology Research Database
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Genetics Abstracts
MEDLINE - Academic
CrossRef

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate CRISCUOLO et al
EISSN 1096-9071
EndPage 2167
ExternalDocumentID PMC7675753
33064340
10_1002_jmv_26605
JMV26605
Genre article
Journal Article
GeographicLocations Italy
GeographicLocations_xml – name: Italy
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3O-
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AI.
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
ECGQY
EJD
ELTNK
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGB
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V2E
VH1
W8V
W99
WBKPD
WHG
WIB
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XPP
XV2
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7TK
7U9
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c5375-d182d88ecb16565f553ffb1226850dc448f5cef7908c0811973a97a090e6dae53
IEDL.DBID DR2
ISSN 0146-6615
1096-9071
IngestDate Thu Aug 21 18:40:34 EDT 2025
Fri Jul 11 11:40:28 EDT 2025
Sat Jul 26 02:18:38 EDT 2025
Thu Apr 03 06:57:11 EDT 2025
Thu Apr 24 23:13:19 EDT 2025
Tue Jul 01 02:24:47 EDT 2025
Wed Jan 22 16:29:58 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords neutralizing activity
COVID-19 diagnostic assays
SARS-CoV-2 serology
Language English
License 2020 Wiley Periodicals LLC.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5375-d182d88ecb16565f553ffb1226850dc448f5cef7908c0811973a97a090e6dae53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-0185-3147
0000-0002-1822-9861
0000-0003-1976-5663
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7675753
PMID 33064340
PQID 2490128356
PQPubID 105515
PageCount 0
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7675753
proquest_miscellaneous_2451859305
proquest_journals_2490128356
pubmed_primary_33064340
crossref_citationtrail_10_1002_jmv_26605
crossref_primary_10_1002_jmv_26605
wiley_primary_10_1002_jmv_26605_JMV26605
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2021
PublicationDateYYYYMMDD 2021-04-01
PublicationDate_xml – month: 04
  year: 2021
  text: April 2021
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: London
– name: Hoboken
PublicationTitle Journal of medical virology
PublicationTitleAlternate J Med Virol
PublicationYear 2021
Publisher Wiley Subscription Services, Inc
John Wiley and Sons Inc
Publisher_xml – name: Wiley Subscription Services, Inc
– name: John Wiley and Sons Inc
References 1988; 44
2020; 6
2020; 58
1997; 16
2020; 5
2020; 323
2014
2020; 20
2020; 52
2020
2020; 7821
e_1_2_10_12_1
e_1_2_10_10_1
e_1_2_10_11_1
e_1_2_10_22_1
Tang MS (e_1_2_10_9_1) 2020; 323
e_1_2_10_20_1
Boukli N (e_1_2_10_16_1) 2020
Zhou X‐H (e_1_2_10_13_1) 2014
Focosi D (e_1_2_10_21_1) 2020; 7821
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
References_xml – volume: 58
  start-page: 514
  year: 2020
  article-title: Evaluation of nucleocapsid and spike protein‐based enzyme‐linked immunosorbent assays for detecting antibodies against SARS‐CoV‐2
  publication-title: J Clin Microbiol
– volume: 7821
  start-page: 437
  year: 2020
  article-title: Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy
  publication-title: Rev Med Virol
– start-page: 1
  year: 2020
  end-page: 8
  article-title: High incidence of false positive results in patients with other acute infections, using the LIAISON® SARS‐CoV‐2 commercial chemiluminescent micro‐particle immunoassay for detection of IgG anti SARS‐CoV‐2 antibodies
  publication-title: J Clin Microbiol
– volume: 52
  start-page: 583
  year: 2020
  end-page: 589
  article-title: SARS‐CoV‐2 vaccines: status report
  publication-title: Immunity
– volume: 6
  start-page: 38
  year: 2020
  end-page: 39
  article-title: SARS‐CoV‐2 infection serology: a useful tool to overcome lockdown?
  publication-title: Cell Death Discov
– volume: 323
  start-page: 1582
  year: 2020
  article-title: Clinical performance of two SARS‐CoV‐2 serologic assays
  publication-title: Clin Chem
– volume: 20
  start-page: 565
  year: 2020
  end-page: 574
  article-title: Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS‐CoV‐2: an observational cohort study
  publication-title: Lancet Infect Dis
– year: 2020
  article-title: Decline of SARS‐CoV‐2‐specific IgG, IgM and IgA in convalescent COVID‐19 patients within 100 days after hospital discharge
  publication-title: Sci China: Life Sci
– year: 2020
– volume: 16
  start-page: 2143
  year: 1997
  end-page: 2156
  article-title: Smooth non‐parametric receiver operating characteristic (ROC) curves for continuous diagnostic tests
  publication-title: Stat Med
– volume: 58
  start-page: e01224
  issue: 9
  year: 2020
  end-page: 20
  article-title: Clinical and analytical performance of an automated serological test that identifies S1/S2 neutralizing IgG in covid‐19 patients semiquantitatively
  publication-title: J Clin Microbiol
– volume: 44
  start-page: 837
  year: 1988
  end-page: 845
  article-title: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach
  publication-title: Biometrics
– year: 2014
– volume: 5
  start-page: 43
  year: 2020
  article-title: Universal coronavirus vaccines: the time to start is now
  publication-title: NPJ Vaccines
– volume: 7821
  start-page: 437
  year: 2020
  ident: e_1_2_10_21_1
  article-title: Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy
  publication-title: Rev Med Virol
– ident: e_1_2_10_10_1
  doi: 10.15557/PiMR.2020.0024
– ident: e_1_2_10_6_1
  doi: 10.1101/2020.03.18.20038018
– ident: e_1_2_10_2_1
  doi: 10.1038/s41420-020-0275-2
– ident: e_1_2_10_15_1
  doi: 10.2307/2531595
– volume-title: Statistical Methods in Diagnostic Medicine
  year: 2014
  ident: e_1_2_10_13_1
– start-page: 1
  year: 2020
  ident: e_1_2_10_16_1
  article-title: High incidence of false positive results in patients with other acute infections, using the LIAISON® SARS‐CoV‐2 commercial chemiluminescent micro‐particle immunoassay for detection of IgG anti SARS‐CoV‐2 antibodies
  publication-title: J Clin Microbiol
– ident: e_1_2_10_17_1
  doi: 10.1101/2020.03.30.20047365
– ident: e_1_2_10_7_1
  doi: 10.1101/2020.07.09.20148429
– ident: e_1_2_10_12_1
– ident: e_1_2_10_19_1
  doi: 10.1016/j.immuni.2020.03.007
– ident: e_1_2_10_18_1
  doi: 10.1038/s41541-020-0198-1
– ident: e_1_2_10_3_1
  doi: 10.1128/JCM.00461-20
– ident: e_1_2_10_5_1
  doi: 10.3389/fmolb.2020.00157
– ident: e_1_2_10_14_1
  doi: 10.1002/(SICI)1097-0258(19971015)16:19<2143::AID-SIM655>3.0.CO;2-3
– ident: e_1_2_10_20_1
  doi: 10.1101/2020.07.21.20159178
– volume: 323
  start-page: 1582
  year: 2020
  ident: e_1_2_10_9_1
  article-title: Clinical performance of two SARS‐CoV‐2 serologic assays
  publication-title: Clin Chem
– ident: e_1_2_10_8_1
  doi: 10.1007/s11427-020-1805-0
– ident: e_1_2_10_4_1
  doi: 10.1016/S1473-3099(20)30196-1
– ident: e_1_2_10_22_1
  doi: 10.1128/JCM.01224-20
– ident: e_1_2_10_11_1
SSID ssj0008922
Score 2.5128613
Snippet Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of...
Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2160
SubjectTerms Algorithms
Animals
Antibodies
Antibodies, Neutralizing
Antibodies, Viral - blood
Chlorocebus aethiops
Comparative analysis
Coronaviridae
Coronaviruses
Correlation analysis
COVID-19
COVID-19 - blood
COVID-19 - epidemiology
COVID-19 - immunology
COVID-19 - virology
COVID-19 Testing - methods
COVID‐19 diagnostic assays
Humans
Immune response
Immunoglobulin G
Immunoglobulin G - blood
Italy - epidemiology
Laboratories
Neutralizing
neutralizing activity
Pandemics
SARS-CoV-2 - immunology
SARS‐CoV‐2 serology
Sensitivity and Specificity
Serologic Tests - methods
Serology
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Vaccines
Vero Cells
Viral diseases
Virology
Title Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.26605
https://www.ncbi.nlm.nih.gov/pubmed/33064340
https://www.proquest.com/docview/2490128356
https://www.proquest.com/docview/2451859305
https://pubmed.ncbi.nlm.nih.gov/PMC7675753
Volume 93
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhAXaHkuFGQQBy7ZJnG8jtVTVVFVlZZDS0sPSJGf6lLIVs0GqT3xE_ob-SXM2EnKUpAQlyiRJy_b4_nGHn9DyBvlU-89kwmAZZMUNmUJoGqbCFMypwsmlMb5jun7yd5RsX_CT1bIVr8XJvJDDBNuqBlhvEYFV7rZvCEN_fz12xisS-AvxVgtBEQHN9RRpYwrCDASJGCDeM8qlOabw53LtugWwLwdJ_krfg0GaPc--dR_eow7ORu3Cz02V7-xOv7nv62Rex0wpduxJ62TFVc_IHem3dL7Q3L-0akzajCZRwyfo12IF4W2mem5vaSBormBa0tr14YplCuwjBT3TmCKCjqrKWadoLinhR5uHxz--H69Mz-GY05jVJiztGk1zg01j8jR7rsPO3tJl64hMZwJnlhwVWxZOqOR0Yd7zpn3OgN8V_LUGvADPTfOC5mWBoBIJgVTUqhUpm5ilePsMVmt57V7SmhRykJOPHOFlkWqhc4yX2Sl5l6oHKzpiLztG64yHZc5ptT4UkUW5ryCGqxCDY7I60H0PBJ4_Eloo2_9qtPhpgLHFK0345MReTUUg_bhkoqq3bxFGZ4hYxw-4knsLMNbGDp3rEhHRCx1o0EAmb2XS-rZaWD4RoYd8CPhN0Mv-fuHV_vT43Dy7N9Fn5O7OQbmhPCjDbK6uGjdC0BWC_0yqNBPVdwisA
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIgGX8i5LWzCIA5dsnThexxKXqlAtpdtDX_SCotixxbaQrdhNJXriJ_Ab-SWdsZOUpSAhLlEiTxK_xvPw-BtCXhaOOee4ikBZNlFaMh6BVl1G0mTc6pTLQqO_Y7Q7GB6m28fieIG8bs_CBHyIzuGGnOHXa2RwdEivX6GGnnw574N4QQDTG5jRG9nyzd4VeFSmwh4CrAURSCHR4gqxZL17dV4aXVMxr0dK_qrBehG0dYd8bCsfIk9O-_VM983Fb7iO_9u6u2Sp0U3pRphM98iCre6Tm6Nm9_0BOftgi1NqMJ9HiKCjTZQXheEZ60n5jXqU5ik8l7SytfeiXIBwpHh8ArNU0HFFMfEExWMtdH9jb__n9x-bkyO4JjQEhtmSTmuN7qHpQ3K49fZgcxg1GRsiI7gUUQnWSpll1mgE9RFOCO6cjkHFywQrDZiCThjrpGKZAV0kVpIXShZMMTsoCyv4I7JYTSr7mNA0U6kaOG5TrVKmpY5jl8aZFk4WCQjUHnnVjlxuGjhzzKrxOQ9AzEkOPZj7HuyRFx3pWcDw-BPRajv8ecPG0xxsUxTgXAx65HlXDAyIuypFZSc10ogYQePwE8thtnR_4Wjf8ZT1iJybRx0BgnvPl1TjTx7kG0F2wJSEZvpp8veK59ujI3_z5N9Jn5Fbw4PRTr7zbvf9CrmdYJyOj0ZaJYuzr7VdA0Vrpp96froEUSUmyQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIlVceEMXChjEgUu2TmznIU5Vy6oUtkItLT0gRfFLLIXsit0g0RM_gd_IL2HGTlKWgoS4RIk8Sfwaz8Pjbwh5UjnmnONFBMqyjoRhPAKt2kSZzrlVgmeVQn_HeD_dPRJ7J_JkhTzrzsIEfIje4Yac4ddrZPCZcZvnoKEfPn0ZgnRB_NJLImU5Wl47B-fYUXkRthBgKYhACMkOVoglm_2ry8LogoZ5MVDyVwXWS6DRVfKuq3sIPDkdNgs11Ge_wTr-Z-OukSutZkq3wlS6TlZsfYOsjdu995tk9tZWp1RjNo8QP0fbGC8KgzNRU_OVeozmOTwbWtvG-1DOQDRSPDyBOSropKaYdoLioRZ6uHVw-OPb9-3pMVwTGsLCrKHzRqFzaH6LHI2ev9nejdp8DZGWPJORAVvF5LnVCiF9pJOSO6diUPByyYwGQ9BJbV1WsFyDJhIXGa-KrGIFs6mprOS3yWo9re06oSIvRJE6boUqBFOZimMn4lxJl1UJiNMBedoNXKlbMHPMqfGxDDDMSQk9WPoeHJDHPeksIHj8iWijG_2yZeJ5CZYpim8u0wF51BcD--GeSlXbaYM0MkbIOPzEnTBZ-r9wtO64YAOSLU2jngChvZdL6sl7D_GNEDtgSEIz_Sz5e8XLvfGxv7n776QPydrrnVH56sX-y3vkcoJBOj4UaYOsLj439j5oWQv1wHPTT-tQJYE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Weak+correlation+between+antibody+titers+and+neutralizing+activity+in+sera+from+SARS%E2%80%90CoV%E2%80%902+infected+subjects&rft.jtitle=Journal+of+medical+virology&rft.au=Criscuolo%2C+Elena&rft.au=Diotti%2C+Roberta+A.&rft.au=Strollo%2C+Marta&rft.au=Rolla%2C+Serena&rft.date=2021-04-01&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=93&rft.issue=4&rft.spage=2160&rft.epage=2167&rft_id=info:doi/10.1002%2Fjmv.26605&rft.externalDBID=10.1002%252Fjmv.26605&rft.externalDocID=JMV26605
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon